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Benign biliary strictures are traditionally managed with balloon dilatation or plastic stents. The use of temporary metal stents in benign strictures is less
well established and requires a removal procedure. Management can be particularly difﬁcult in cases of altered surgical anatomy. We describe our ﬁrst
experience with percutaneous placement of a biodegradable stent for an anastomotic biliary stricture. Following an iatrogenic bile duct injury managed
with choledochojejunostomy, a 66-year-old female patient developed a stricture at the implantation site, causing biliary obstruction. Endoscopic access
was precluded because of the surgery, necessitating percutaneous transhepatic biliary intervention. The stricture was unresponsive to percutaneous
balloon dilatation, requiring external drainage. A biodegradable stent was placed easily across the stricture to attempt long-term stricture remodeling.
The stent maintained patency while in situ, but cholangitis occurred during stent degradation. Long-term patency was not achieved owing to the nature of
the stricture. Percutaneous biodegradable stenting of biliary strictures is technically feasible with standard methods. Intuitively, this is an appealing
concept for treating anastomotic biliary strictures and warrants further research.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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Benign biliary strictures can occur as a result of cholelithiasis,
pancreatitis, or iatrogenic injury. Benign strictures are traditionally
managed with balloon dilatation and insertion of plastic stents
during endoscopic retrograde cholangiopancreatography.1 To avoid
blockage and sepsis, plastic stents should be replaced every 3
months. Although long-term stricture remodeling can be achieved
in up to 80% of cases, this requires multiple endoscopic retrograde
cholangiopancreatography procedures and multiple balloon di-
latations over several months.2,3 Covered or uncovered self-
expandable metal stent (SEMS) insertion is traditionally reserved
for long-term in situ palliation of malignant biliary obstruction,
where removal of the stent is less of a concern. Uncovered SEMS
should not be placed through benign strictures as removal is not
possible once the stent has embedded.4–6 Short-term, retrievable,
covered SEMS have recently been used in the management of
benign biliary strictures with some success.7,8 However, stents may
migrate or become trapped bymucosal overgranulation at the ends
of the stent,9 and endoscopic removal cannot be guaranteed. If
endoscopic access is precluded owing to altered anatomy, both
placement and removal can be challenging or impossible. In addi-
tion, some studies suggest an increased change in stent migration
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ment for reintervention, and the ability to be placed in cases of
altered surgical anatomy. Biodegradable stents meet these criteria.
They are licensed for benign esophageal strictures, but are not yet
licensed for use outside of the esophagus. Custom-made biliary
stents are available on request from themanufacturer.We report on
a case of biodegradable stent insertion for the management of a
benign biliary stricture at a biliary-enteric anastamosis.Case report
A 66-year-old lady required a choledochojejunostomy following
iatrogenic bile duct injury during cholecystectomy. One year later,
she developed obstructive jaundice because of a stricture at the
biliary-enteric anastomosis.
Percutaneous transhepatic cholangiographywas performed; the
1-cm stricture was easily dilated with a 10 mm  40 mm Evercross
balloon dilatation catheter (ev3 Inc., Plymouth, MN, USA), but there
was immediate recoil of the segment resulting in ongoing
obstruction.
Permission was obtained from the Hospital Institutional Review
Board and the national Medicines and Healthcare Products Regu-
latory Agency for insertion of a custom-made biodegradable poly-
dioxanone stent on a named patient basis.ion Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK.
vier. Open access under CC BY-NC-ND license.
Fig. 1. Loading of stent. The biodegradable stent ismanually loaded into the (A)13F delivery systemand (B, C) the sheath advancedover it until fully containedwithin thedelivery system.
Damian Mullan et al. / Biodegradable Biliary Stents 59The stent was a smaller version of the currently licensed
biodegradable esophageal stent Ella-SX BD (Ella-CS, Hradec Kra-
love, Czech Republic). This was supplied separate from the 13F
delivery system anddsimilar to the esophageal versiondrequired
hand loading beforehand (Fig. 1).
At the time of the procedure, a 10F percutaneous internal–
external drain was in situ across the anastomosis (Fig. 2). A Super
Stiff Amplatz wire (Boston Scientiﬁc, St Albans, UK) was placed, the
drain removed, and a 13F vascular sheath inserted.
The radiolucent stent was placed centered on the anastomosis
with the two radiopaque markers above and below (Fig. 3).
Following stent deployment, there was good expansion and free
antegrade ﬂow of contrast.
A 10F internal–external drain was again placed across the
anastomosis. Two months after the procedure, the patient devel-
oped signs of biliary sepsis with debris evident within the stent on
cholangiography. The debris was easily displaced with injection of
saline, and the patient commenced regular saline ﬂushes at home.
Four months after the procedure, the stent had begun to
disintegrate as evidenced by the fact that only the upper markers
were still visible in situ.Fig. 2. Stricture and dilatation. (A) Anastomotic stricture (arrow) with 10F internal–exte
demonstrating compression of the balloon at the tightest point of the stricture (arrow).Following complete disintegration of the stent 5 months after
the procedure, the strictured segment collapsed again, resulting in
ongoing obstruction. Subsequently, the patient underwent further
surgery and revision of the anastomosis.
Discussion
Biodegradable stents are constructed with woven poly-
dioxanone, a biodegradable synthetic polymer that has been more
traditionally used in absorbable surgical sutures. Biodegradable
stents have been successfully placed in various hollow organs
throughout the human body.11–16 The stents degrade by hydrolysis.
Although in vitro the stent disintegration is accelerated in an acidic
environment, in practice in the human body, stents tend to stay
intact for at least 3 months with evidence of further stent disinte-
gration over the ensuing weeks.
The 13F biodegradable stent delivery system is larger than a
conventional 8F biliary SEMS system; however, with appropriate
measures to fashion a slightly larger than normal transhepatic
track, biodegradable stents can be readily deployed with a very
conventional approach. Operators need to be aware to use an extrarnal drain passing through the strictured segment. (B) Balloon dilatation to 9 mm,
Fig. 3. Placement of stent. (A) Delivery system containing the radiolucent stent is inserted across the anastomotic stricture. The radio-opaque markers woven into stent (black
arrows) identify the upper and lower end of the stent. (B) Balloon dilation is performed. (C) Contrast injection conﬁrms expansion and correct placement. There is a marker on the
transhepatic introducer sheath (white arrow).
Gastrointestinal Intervention 2015 4(1), 58–6060stiff guide wire to allow free passage of the 13F system, and be
cognizant of the fact that the stent is radiolucent, with radiopaque
markers at both ends.
Stents placed in the biliary tree above an intact sphinctermay be
at risk of biliary colic and sepsis during stent disintegration. This
should be less of an issue with patients receiving stents across a
biliary-enteric anastomosis as the stent fragments should simply
fall into the bowel. Our patient, however, developed chol-
angitisdraising the question whether prophylactic antibiotics
should be given routinely until stent degradation is complete.
Biodegradable stents are placed in benign strictures with an aim
of achieving stricture expansion and long-term stricture remodel-
ing, while disintegration occurs over a 12- to 16-week period, thus
potentially avoiding repeated intervention.
In our patient, there was no sustained success from the biliary-
enteric biodegradable stent insertion; however, this was probably
because the narrowed segment was of a long ﬂoppy nature,
possibly due to anastomotic dehiscence and remodeling rather
than a focal ﬁbrotic stricture.
As a consequence of the increasing number of patients receiving
radical pancreaticoduodenectomy as well as liver transplantation,
in the future more patients will present with anastomotic strictures
of the bile duct reimplantation site. These are often not endo-
scopically accessible and will mandate a percutaneous approach for
stent placement and removal. Percutaneous SEMS removal is
technically possible but is not yet widely reported.17 Biodegradable
stents may provide a valuable addition to the options available, but
improved delivery systems and revised licensing is required to
make this a standard approach.
Conﬂicts of interest
The authors declare no conﬂicts of interest.
References
1. Draganov P, Hoffman B, Marsh W, Cotton P, Cunningham J. Long-term outcome
in patients with benign biliary strictures treated endoscopically with multiple
stents. Gastrointest Endosc. 2002;55:680–6.2. Libby ED, Leung JW. Prevention of biliary stent clogging: a clinical review. Am J
Gastroenterol. 1996;91:1301–8.
3. Costamagna G, PandolﬁM, Mutignani M, Spada C, Perri V. Long-term results of
endoscopic management of postoperative bile duct strictures with increasing
numbers of stents. Gastrointest Endosc. 2001;54:162–8.
4. Foerster EC, Hoepffner N, Domschke W. Bridging of benign choledochal ste-
noses by endoscopic retrograde implantation of mesh stents. Endoscopy. 1991;
23:133–5.
5. Deviere J, Cremer M, Baize M, Love J, Sugai B, Vandermeeren A. Management of
common bile duct stricture caused by chronic pancreatitis with metal mesh self
expandable stents. Gut. 1994;35:122–6.
6. Dumonceau JM, Deviere J, Delhaye M, Baize M, Cremer M. Plastic and metal
stents for postoperative benign bile duct strictures: the best and the worst.
Gastrointest Endosc. 1998;47:8–17.
7. Moon JH. Covered self-expandable metal stents for the treatment of benign
biliary strictures after liver transplantation: when and how? Dig Dis Sci. 2013;
58:2449–51.
8. Irani S, Baron TH, Akbar A, Lin OS, Gluck M, Gan I, et al. Endoscopic treatment of
benign biliary strictures using covered self-expandable metal stents (CSEMS).
Dig Dis Sci. 2014;59:152–60.
9. Tringali A, Blero D, Boskoski I, Familiari P, Perri V, Deviere J, et al. Difﬁcult
removal of fully covered self expandable metal stents (SEMS) for benign
biliary strictures: the “SEMS in SEMS” technique. Dig Liver Dis. 2014;46:
568–71.
10. Tarantino I, Mangiavillano B, Di Mitri R, Barresi L, Mocciaro F, Granata A, et al.
Fully covered self-expandable metallic stents in benign biliary strictures: a
multicenter study on efﬁcacy and safety. Endoscopy. 2012;44:923–7.
11. Mullan D, O’Dwyer ST, Laasch H-U. Benign anastomotic stricture of the rectum
complicated by metal stent insertion: salvage by placement of a biodegradable
polydioxanone stent. Gastrointest Interv. 2013;2:59–61.
12. Stivaros SM, Williams LR, Senger C, Wilbraham L, Laasch HU. Woven poly-
dioxanone biodegradable stents: a new treatment option for benign and ma-
lignant oesophageal strictures. Eur Radiol. 2010;20:1069–72.
13. Repici A, Vleggaar FP, Hassan C, van Boeckel PG, Romeo F, Pagano N, et al.
Efﬁcacy and safety of biodegradable stents for refractory benign esophageal
strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest
Endosc. 2010;72:927–34.
14. Grifﬁths EA, Gregory CJ, Pursnani KG, Ward JB, Stockwell RC. The use of
biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign
and malignant oesophageal disease. Surg Endosc. 2012;26:2367–75.
15. Petrtyl J, Bruha R, Horak L, Zadorova Z, Dosedel J, Laasch HU. Management of
benign intrahepatic bile duct strictures: initial experience with polydioxanone
biodegradable stents. Endoscopy. 2010;42:E89–90.
16. Janik V, Horak L, Hnanicek J, Malek J, Laasch HU. Biodegradable polydioxanone
stents: a new option for therapy-resistant anastomotic strictures of the colon.
Eur Radiol. 2011;21:1956–61.
17. Gwon DI, Ko GY, Ko HK, Yoon HK, Sung KB. Percutaneous transhepatic
treatment using retrievable covered stents in patients with benign biliary
strictures: mid-term outcomes in 68 patients. Dig Dis Sci. 2013;58:3270–9.
